I-Baricitinib: yenzelwe ini, ungayithatha kanjani nemiphumela engemihle

-Delile

• Yenzelwe ini
• Ngabe i-baricitinib inconyelwe ukwelashwa kwe-COVID-19?
• Ungathatha kanjani
• Imiphumela emibi engaba khona
• Ngubani ongafanele asebenzise

IBaricitinib ikhambi elinciphisa ukuphendula kwamasosha omzimba, kunciphisa ukusebenza kwama-enzyme akhuthaza ukuvuvukala nokuvela komonakalo ohlangene ezimweni zesifo samathambo. Ngale ndlela, leli khambi liyakwazi ukunciphisa ukuvuvukala, likhulule izimpawu zesifo njengobuhlungu nokuvuvukala kwamalunga.

Lo muthi uvunywa yi-Anvisa ukuthi usetshenziswe ku-rheumatoid arthritis, enegama lokuhweba i-Olumiant futhi ungathengwa emakhemisi kuphela ngomuthi kadokotela, ngohlobo lwamaphilisi ama-2 noma ama-4 mg.

Yenzelwe ini

I-Baricitinib ikhonjiswa ukuthi inciphisa ubuhlungu, ukuqina nokuvuvukala kwesifo samathambo, ngaphezu kokwehlisa ukukhula kokulimala kwamathambo nokuhlangana.

Lo muthi ungasetshenziswa wedwa noma uhlanganiswe ne-methotrexate, ekwelashweni kwesifo samathambo.

Ngabe i-baricitinib inconyelwe ukwelashwa kwe-COVID-19?

IBaricitinib igunyazwe kuphela e-United States ukwelapha ukutheleleka nge-coronavirus entsha esolwayo noma iqinisekiswe ukuhlolwa kwe-laboratory, lapho isetshenziswa ngokuhlangana ne-remdesivir, eyi-antiviral. I-Remdesivir igunyazwe yi-Anvisa yezifundo zokuhlola zeCovid-19.

Olunye ucwaningo lukhombisile ukuthi lo muthi ungasiza ukuvimba ukungena kwe-coronavirus kumaseli futhi kunciphise isikhathi sokutakula nokufa ezimeni ezilinganiselayo kuya kwezinzima, kubantu abadala abasesibhedlela nezingane ezingaphezu kweminyaka emibili abadinga i-oxygen, i-ventilation mechanical noma i-oxygenation nge-extracorporeal membrane. Bheka zonke izidakamizwa ezivunyiwe nezitadiswayo zeCovid-19.

Ngokusho kuka-Anvisa, ukuthengwa kwe-baricitinib ekhemisi kusavumelekile, kodwa kuphela kubantu abanemibhalo kadokotela wesifo samathambo.

Ungathatha kanjani

IBaricitinib kufanele ithathwe ngomlomo ngokweseluleko sezokwelapha, kanye ngosuku, ngaphambi noma ngemuva kokudla.

Ithebhulethi kufanele njalo iphuzwe ngasikhathi sinye, kepha uma kwenzeka ukhohlwa, umthamo kufanele uphuzwe ngokushesha nje lapho ukhumbula bese ulungisa amashejuli ngokwalo mthamo wokugcina, uqhubeke nokwelashwa ngokwezikhathi ezintsha ezihleliwe. Musa ukusiphinda kabili isilinganiso sokwenza umthamo okhohliwe.

Ngaphambi kokuqala ukwelashwa nge-baricitinib, udokotela kufanele ancoma ukuthi uhlolwe ukuqinisekisa ukuthi awunaso isifo sofuba noma ezinye izifo.

Imiphumela emibi engaba khona

Eminye yemiphumela emibi kakhulu engahle yenzeke ngenkathi welashwa nge-baricitinib ukusabela okweqile ezingxenyeni zepilisi, isicanucanu noma ingozi eyengeziwe yokutheleleka okubandakanya isifo sofuba, ukhunta, ukutheleleka kwamagciwane noma amagciwane njenge-herpes simplex noma i-herpes zoster.

Ngaphezu kwalokho, i-baricitinib ingakhuphula ubungozi bokuthola i-lymphoma, i-vein thrombosis ejulile noma i-pulmonary embolism.

Kunconywa ukuyeka ukusetshenziswa futhi ufune usizo lwezokwelapha ngokushesha uma kuvela izimpawu zokungezwani komzimba ne-baricitinib, njengokuphefumula kanzima, umuzwa wokuqina emphinjeni, ukuvuvukala emlonyeni, ulimi noma ubuso, noma isifuba, noma uma uthatha i-baricitinib ngemithamo emikhulu kunaleyo enconyelwe ukulandela izimpawu nezimpawu zemiphumela emibi.

Ngubani ongafanele asebenzise

I-Baricitinib akufanele isetshenziswe ngabesifazane abakhulelwe noma abancelisayo, ezimweni zesifo sofuba noma izifo zokukhunta ezifana ne-candidiasis noma i-pneumocystosis.

Lo muthi kufanele usetshenziswe ngokuqapha kubantu abanezinkinga zokuvala igazi, kufaka phakathi abantu asebekhulile, abantu abakhuluphele, abantu abanomlando we-thrombosis noma i-embolism noma abantu abazothola uhlobo oluthile lokuhlinzwa futhi badinga ukukhubazeka. Ngaphezu kwalokho, kufanele kuqashelwe futhi kubantu abanokukhubazeka kwesibindi noma ukusebenza kwezinso, i-anemia noma abantu abanamasosha omzimba abuthakathaka, abangadinga ukulungiswa komthamo ngudokotela.